tiprankstipranks
ESSA Pharma Reports Progress in Masofaniten Study
PremiumCompany AnnouncementsESSA Pharma Reports Progress in Masofaniten Study
3M ago
Essa Pharma: Masofaniten, enzalutamide continue to be well tolerated
PremiumThe Fly
Essa Pharma: Masofaniten, enzalutamide continue to be well tolerated
3M ago
Biotech Alert: Searches spiking for these stocks today
PremiumThe Fly
Biotech Alert: Searches spiking for these stocks today
3M ago
Essa Pharma presents Phase 1 clinical data of masofaniten in prostate cancer
PremiumThe FlyEssa Pharma presents Phase 1 clinical data of masofaniten in prostate cancer
6M ago
Essa Pharma presents updated Phase 1 Masofaniten clinical data
PremiumThe Fly
Essa Pharma presents updated Phase 1 Masofaniten clinical data
6M ago
Biotech Alert: Searches spiking for these stocks today
PremiumThe Fly
Biotech Alert: Searches spiking for these stocks today
6M ago
Essa Pharma reports Q3 EPS (17c), consensus (19c)
PremiumThe FlyEssa Pharma reports Q3 EPS (17c), consensus (19c)
9M ago
ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal Third Quarter Ended June 30, 2023
PremiumPress Releases
ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal Third Quarter Ended June 30, 2023
9M ago
Essa Pharma assumed with an Outperform at Oppenheimer
PremiumThe Fly
Essa Pharma assumed with an Outperform at Oppenheimer
10M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100